Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma

Meiying Song,Luoyang Wang,Suli Jiang, Jie Liang,Wei Li,Wei Rao,Qiaochu Du,Guixian Liu,Haining Meng,Lei Tang,Zhifei Li,Yanyan Yang,Li Zhang,Bei Zhang

International immunopharmacology（2024）

引用 0|浏览4

暂无评分

摘要

•Blocking PD-L1 promotes pathogenic Th17 cell infiltration and activation in the liver, and exacerbate liver fibrosis.•IL-17A-neutralizing antibody combined with anti-PD-L1 antibody treatment inhibited hepatocellular carcinoma tumor growth and demonstrated significant anti-tumor efficacy in mice.•IL-17A/STAT3 signaling pathway upregulates PD-L1 expression.

查看译文

关键词

Liver cancer,Anti-PD-L1,Anti-IL-17A,Immunotherapy Checkpoint blockade,Combination therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要